Skip to main content
Figure 3 | BMC Medicine

Figure 3

From: Next generation sequencing and tumor mutation profiling: are we ready for routine use in the oncology clinic?

Figure 3

Kimberly Blackwell, MD is professor of medicine and assistant professor of radiation oncology at Duke University Medical Center and director of the breast cancer program at the Duke Cancer Institute, where she oversees all basic and translational research programs involving breast cancer patients. She has played a major role in two recently approved breast cancer drugs, lapatinib and T-DM1, both of which were studied in her laboratory and developed in trials in which she served as principal investigator.

Back to article page